Compare LAES & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | RXST |
|---|---|---|
| Founded | 2022 | 1997 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.0M | 417.3M |
| IPO Year | N/A | 2021 |
| Metric | LAES | RXST |
|---|---|---|
| Price | $4.87 | $12.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | $6.00 | ★ $11.30 |
| AVG Volume (30 Days) | ★ 16.1M | 845.0K |
| Earning Date | 12-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,978,000.00 | ★ $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.75 |
| 52 Week Low | $0.35 | $6.32 |
| 52 Week High | $11.00 | $44.22 |
| Indicator | LAES | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 75.78 |
| Support Level | $4.16 | $11.20 |
| Resistance Level | $5.10 | $10.12 |
| Average True Range (ATR) | 0.44 | 0.70 |
| MACD | 0.09 | 0.23 |
| Stochastic Oscillator | 87.79 | 89.45 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.